Union Health Ministry Proposes Swift Action Against Substandard Medicines

Immediate Suspension of Manufacturing Licenses Proposed

New Delhi: On Wednesday, the Union health ministry announced a proposal to immediately suspend manufacturing licenses for drugs that fail to meet standard quality (NSQ) on critical parameters such as assay, dissolution, and sterility. This initiative aims to expedite regulatory actions against substandard pharmaceuticals.

The suggested changes to the Drugs Rules of 1945 would empower either the Central License Approving Authority or the State Licensing Authority to suspend a drug's manufacturing license upon receiving a government analyst's report that identifies it as NSQ based on any of the specified criteria.

The draft amendments have been made public for consultation, allowing stakeholders and the general public to submit objections and suggestions within 30 days from the date the Gazette of India publishes the draft rules.

Concerns and feedback can be directed to the Under Secretary (Drugs) at the Ministry of Health and Family Welfare, as stated in the announcement.

These amendments are designed to facilitate quick regulatory responses when substandard medicines are detected, preventing their ongoing production and distribution, and enhancing compliance with established quality standards to protect patient safety and public health.

Currently, the Drugs Rules of 1945 require a regulatory process, including a show-cause notice, before a manufacturing license can be suspended or canceled. This can create delays between a drug being declared NSQ and the initiation of regulatory measures, allowing potentially harmful drugs to remain on the market.

To mitigate this issue, the ministry has proposed that the Central or State Licensing Authority can immediately suspend a drug's manufacturing license upon receiving a report from a government analyst that identifies it as NSQ concerning Assay, Dissolution, Related Substances, Impurities, or Sterility.

These parameters are essential for assessing the quality of medications. The proposed changes aim to ensure that any non-compliance with these critical parameters triggers prompt regulatory action, thereby reducing risks to patients.

Additionally, the amendments stipulate that corrective actions must be taken before the suspension can be lifted.

The suspension will remain in effect until the manufacturer conducts a thorough Root Cause Analysis to determine the reasons for the quality failure and implements suitable Corrective and Preventive Actions (CAPA) that satisfy the licensing authority.

The suspension can only be revoked after the necessary corrective measures have been implemented and verified by the licensing authority.

This approach is intended to ensure that identified quality issues are properly addressed and that safeguards are established to prevent future occurrences.

To enhance regulatory coordination and ensure timely responses, further amendments to Form 13, which pertains to the government analyst's test report, have also been proposed.

Under the new system, the government analyst's report will be shared with the Drugs Controller General of India (DCGI), the relevant state and Union territory licensing authorities, as well as the manufacturer and marketer of the drug in question.

These proposals follow discussions at the 65th meeting of the Drugs Consultative Committee (DCC) on December 20, 2024, and the recommendations from the 92nd meeting of the Drugs Technical Advisory Board (DTAB) on April 24, 2025.

The anticipated amendments are expected to enhance post-marketing regulatory oversight, enable timely actions against substandard drugs, foster greater accountability among manufacturers and marketers, and bolster public trust in the quality of medicines available in the country.